Glaxo places PR business for HIV drugs under review

Share this article:

GlaxoSmithKline has placed the PR business for its HIV medications franchise in review.
The incumbent agency, Chicagobased PCI Public Communications, is not participating in the review.
A GSK spokeswoman declined to comment on the review, citing corporate policy that "any of our agency dealings is confidential."

 

Share this article:

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.